Oncoinvent ASA

Oncoinvent AS is a biotechnology startup based in Norway that was founded in 2010. The company's slogan, "Innovations for better cancer care," encapsulates its mission to develop new and innovative radiopharmaceutical products for improved treatment options for cancer patients. Its lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere suspension designed to treat metastatic cancers in body cavities. This product has demonstrated strong and consistent anticancer activity in preclinical studies at non-toxic doses, potentially able to treat several forms of metastatic cancer. Oncoinvent's headquarters in Oslo is equipped with modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The company's development programs focus on radiotherapeutic and radioimmunotherapeutic products, with an emphasis on alpha-emitting radionuclides for treating different solid cancers. The company recently secured a significant investment of kr250.00M in a Venture Round investment on 29 June 2021. The investors in this round included Canica, Hadean Partners, Watrium, MUSST Investments, MP Pensjon, Sundt AS, and Geveran Trading. Oncoinvent's innovative approach and promising product pipeline make it a compelling player in the biotechnology space with potential for significant impact on cancer care.